Biography
Carin A. Uyl-de Groot studied Health Care Policy and Management at the Erasmus University Rotterdam. From March 1990 onwards she is working at the institute for Medical Technology Assessment/Department of Health Care Policy and Management at the Erasmus Medical Centre Rotterdam. Her research activities are mainly focused on cost-effectiveness analyses of cancer treatments. Quality of life studies are an integral part of these studies. From 1994 she is program leader of cancer studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, methodological issues and implementation studies particularly in the cancer field. She got her PhD in 1995. Since March 2000 she is director of the institute for Medical Technology Assessment. Since November 2005 she has been appointed professor of health technology assessment at the VU University Medical Center in Amsterdam.
Erasmus School of Health Policy & Management
Full professor | Health Technology Assessment (HTA)
- uyl@eshpm.eur.nl
- Location
- Burg. Oudlaan 50, Rotterdam
More information
Work
- Lj Bakker, Fw Thielen, Wk Redekop, CA Uyl de Groot & Hm Blommestein (2023) - Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma - BMC Medical Research Methodology, 23 (1) - doi: 10.1186/s12874-023-01952-2 - [link]
- Anna M. Smak Gregoor, Tobias E. Sangers, Lytske J. Bakker, Loes Hollestein, Carin A. Uyl – de Groot, Tamar Nijsten & Marlies Wakkee (2023) - An artificial intelligence based app for skin cancer detection evaluated in a population based setting - npj Digital Medicine, 6 (1) - doi: 10.1038/s41746-023-00831-w - [link]
- Remziye Zaim, Ken Redekop & Carin A Uyl-de Groot (2023) - Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment - Frontiers in Health Services, 3 - doi: 10.3389/frhs.2023.1034256
- Remziye Zaim, W. Ken Redekop & Carin A. Uyl-de Groot (2023) - Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer - Frontiers in Oncology, 13, 1027659 - doi: 10.3389/fonc.2023.1027659 - [link]
- Remziye Zaim, Ken Redekop & Carin A Uyl-de Groot (2023) - Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer - Journal of Cancer Policy, 35 - doi: 10.1016/j.jcpo.2022.100382
- Marianne Luyendijk, Hedwig Blommestein, Carin Uyl-de Groot, Sabine Siesling & Agnes Jager (2023) - Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands - JAMA network open, 6 (2) - doi: 10.1001/jamanetworkopen.2022.56170 - [link]
- Anne Kleijburg, C. Louwrens Braal, Justin D. Westenberg, Agnes Jager, Stijn L.W. Koolen, Ron H.J. Mathijssen, Carin A. Uyl-de Groot, Pim Wetzelaer & Hannah Penton (2023) - Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands - Biomedicine and Pharmacotherapy, 158 - doi: 10.1016/j.biopha.2022.114158 - [link]
- Yi Hsuan Chen, Hedwig M. Blommestein, Reinder Klazenga, Carin Uyl-de Groot & Marco van Vulpen (2023) - Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands - Cancers, 15 (2) - doi: 10.3390/cancers15020516 - [link]
- Martijn J H G Simons, Carin A Uyl-de Groot, Valesca P Retèl, Joanne M Mankor, Bram L T Ramaekers, Manuela A Joore & Wim H van Harten (2023) - Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer - Value in Health, 26 (1), 71-80 - doi: 10.1016/j.jval.2022.07.006 - [link]
- Leonarda Bremmers, Leona Hakkaart-van Roijen, Leonoor Gräler, Carin Uyl-de Groot & Isabelle Fabbricotti (2022) - How Do Shifts in Patients with Mental Health Problems’ Formal and Informal Care Utilization Affect Informal Caregivers?: A COVID-19 Case Study - International Journal of Environmental Research and Public Health, 19 (24) - doi: 10.3390/ijerph192416425 - [link]
- Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran
Cie Beoordeling Oncologische Middelen
- Start date approval
- July 2022
- End date approval
- July 2025
- Place
- UTRECHT
Gezondheidsraad
- Start date approval
- July 2022
- End date approval
- July 2025
- Place
- DEN HAAG
bestuurslid CPO, Erasmus Medisch Centrum
- Start date approval
- July 2022
- End date approval
- July 2025
- Place
- ONBEKEND
Master Thesis HE
- Year Level
- master, master
- Year
- 2022
- Course Code
- GW4592M
Module Knowledge
- Level
- bachelor 1
- Year Level
- bachelor 1
- Year
- 2022
- Course Code
- GW114K
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2022
- Course Code
- GW4555M
f